Back to discover

Protein / target

Mismatch repair endonuclease PMS2

Encoded byPMS2P54278Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Single base insertion or deletion binding

Strongest disease association

Inherited cancer-predisposing syndrome

Via encoding gene PMS2 · Genetic evidence · score 0.95

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Component of the post-replicative DNA mismatch repair system (MMR).

View complete UniProt function annotation

Component of the post-replicative DNA mismatch repair system (MMR) (PubMed:30653781, PubMed:35189042). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Possesses an ATPase activity, but in the absence of gross structural changes, ATP hydrolysis may not be necessary for proficient mismatch repair (PubMed:35189042)

Subcellular location

Nucleus
Domains and Gene Ontology detail (14)

Gene Ontology

  • CMutLalpha complex
  • Cnucleoplasm
  • Cnucleus
  • FATP binding
  • FATP hydrolysis activity
  • FATP-dependent DNA damage sensor activity
  • FDNA binding
  • Fendonuclease activity
  • Fsingle base insertion or deletion binding
  • Pmeiotic mismatch repair
  • Pmismatch repair
  • Ppositive regulation of isotype switching to IgA isotypes

862 aa · 96 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell-cycle regulationUniProt
View supporting evidence

Cell-cycle regulation

  • ·Component of the post-replicative DNA mismatch repair system (MMR) (PubMed:30653781, Pub…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PMS2

Gene-level evidence surfaced through the gene PMS2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Colorectal Neoplasms, Hereditary Nonpolyposis
0.97Well supported

Genetic evidence dominant · Open Targets 0.87

Inherited cancer-predisposing syndrome
0.95Well supported

Genetic evidence dominant · Open Targets 0.58

Neoplastic Syndromes, Hereditary
0.95Well supported

Genetic evidence dominant · Open Targets 0.58

Endometrial Neoplasms
0.91Well supported

Genetic evidence dominant · Open Targets 0.65

View evidence synthesis (4)
Colorectal Neoplasms, Hereditary NonpolyposisWell supported
0.97
agreement 0.861.00
Genetic62%Somatic mutation32%Literature6%Genetic literaturedup

Open Targets aggregate 0.87 · 3 independent evidence families · 1 not counted as duplicate

Inherited cancer-predisposing syndromeWell supported
0.95
agreement 0.811.00
Genetic99%Literature1%

Open Targets aggregate 0.58 · 2 independent evidence families

Neoplastic Syndromes, HereditaryWell supported
0.95
agreement 0.811.00
Genetic99%Literature1%

Open Targets aggregate 0.58 · 2 independent evidence families

Endometrial NeoplasmsWell supported
0.91
agreement 0.801.00
Genetic72%Somatic mutation25%Literature3%Genetic literaturedup

Open Targets aggregate 0.65 · 3 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Colorectal Neoplasms, Hereditary Nonpolyposis0.87
Endometrial Neoplasms0.65
Inherited cancer-predisposing syndrome0.58
Neoplastic Syndromes, Hereditary0.58

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)
SM · Structure with LigandPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.